Table 1.

Anthropometric characteristics of the investigated patients (n = 43). Data are expressed as mean (95% confidence interval)

	Control group (n = 22)	CKD group (n = 11)	Haemodialysis group (n = 10)
Gender (M/F)	12/10	5/6	5/5
Age (years)	36 (32, 41)	51 (46, 56)	41 (35, 47)
Weight (kg)	72.0 (68.3, 75.7)	70.8 (64.8, 76.7)	63.8 (55.9, 71.7)
Height (m)	1.69 (1.66, 1.72)	1.61 (1.56, 1.65)	1.66 (1.61, 1.72)
BMI ( kg m – 2 )	25.1 (24.1, 26.1)	27.8 (26.0, 28.7)	22.8 (21.2, 24.4)
CL creatinine (ml min – 1 1. 73 m – 2 )	108 (98, 118)	33 (26, 40)	9 (7, 11)
CYP2D6 phenotype	EM	EM	EM
Basal HR	67 (64, 71)	69 (63, 75)	77 (70, 84)‡
HR (d‐nebivolol, t max )	63 (60, 67)*	65 (59, 72)*	74 (68, 80)*, ‡
Baseline SBP (mmHg)	123 (117, 130)	141 (127, 155)†	133 (122, 145)
SBP (d‐nebivolol, t max )	117 (111, 122)*	134 (120, 149)*	130 (122, 138)
Baseline DBP (mmHg)	72 (68, 77)	84 (72, 96)	83 (76, 86)
DBP (d‐nebivolol, t max )	67 (63, 71)*	82 (72, 92)	82 (78, 89)
Associated drugs	5, 6, 9, 11, 18, 19, 22, 23, 24, 25	1, 5, 6, 9, 10, 11, 14, 15, 17, 18, 19	1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17, 18, 19, 20

BMI, body mass index; CKD, chronic kidney disease; CL, clearance; CYP, cytochrome P450; DBP, diastolic blood pressure, EM, extensive metabolizers of cytochrome P450 2D6; F, female; HR, heart rate; M, male; SBP, systolic blood pressure; t _max, maximum concentration. 1 = folic acid; 2 = complex B; 3 = acetylsalicylic acid; 4 = omeprazole; 5 = enalapril; 6 = furosemide; 7 = simvastatin; 8= calcitriol; 9 = captopril; 10 = amlodipine; 11 = hydrochlorothiazide; 12 = diazepam; 13 = sevelamer; 14 = allopurinol; 15 = erythropoietin; 16 = vitamin C; 17 = ferrous sulfate; 18 = losartan; 19 = atorvastatin; 20 = cyclobenzaprine; 21 = indapamide; 22 = levothyroxine; 23 = spironolactone; 24 = olmesartan.

^* P < 0.05 baseline vs. t _max;

^† P < 0.05 CKD vs. control group;

^‡ P < 0.05 haemodialysis vs. control group.